Original Publication Date: 1 August, 2014
Publication / Source: Personalized Medicine
Authors: Kevin C Soares, Lei Zheng, Nita Ahuja
With the US FDA’s approval of the first cancer vaccine for prostate cancer  and immune checkpoint blockade therapy against CTLA-4 for melanoma , the complex interaction between antitumor immune responses and tumor immune evasion is being intensely scrutinized. Despite a number of exciting preclinical studies and clinical research, most novel immunotherapies have demonstrated limited efficacy in early-phase clinical trials. The reason for this is multifactorial.